Use of Edaravone to Decrease Perioperative Neurocognitive Disorders in Elderly Patients with Hip Replacement
The management of perioperative neurocognitive disorders (PND) and postoperative delirium (POD) in elderly patients undergoing hip replacement surgery remains a critical clinical challenge. A recent randomized controlled trial by Xi et al. (2021) investigated the effects of edaravone, a free radical scavenger, on reducing these complications. While their findings suggested a significant reduction in POD and PND incidence, several methodological and interpretative concerns necessitate further scrutiny to validate the conclusions and ensure clinical applicability.
Study Design and Primary Outcomes
The trial enrolled elderly patients (mean age >72 years) undergoing hip replacement surgery, randomizing them into edaravone and control groups. Edaravone was administered intravenously at 30 mg twice daily for three days postoperatively. The primary outcomes included the incidence of POD within seven days post-surgery and the incidence of PND at one and twelve months post-surgery. Secondary outcomes assessed cognitive function via the modified Telephone Interview for Cognitive Status (TICS-m) and activities of daily living (ADL) scores.
Xi et al. reported a statistically significant reduction in POD incidence within seven days (edaravone group: 8.7% vs. control: 21.8%) and lower PND rates at one month (edaravone: 9.7% vs. control: 26.7%) and twelve months (edaravone: 11.7% vs. control: 28.3%). Additionally, the edaravone group demonstrated shorter hospital stays (9.1 ± 2.3 days vs. 10.7 ± 2.5 days). Serum levels of CXC chemokine ligand-13 (CXCL13), a biomarker associated with neuroinflammation, were also reduced in the edaravone group, suggesting a potential mechanism via anti-inflammatory and antioxidative pathways.
Critical Appraisal of Methodological Considerations
1. Preoperative Risk Factors and Baseline Characteristics
A key limitation of the study lies in the incomplete assessment of preoperative risk factors known to influence PND and POD. While the Montreal Cognitive Assessment (MoCA) was used to evaluate baseline cognitive function, the authors did not account for neuropsychiatric comorbidities such as anxiety, depression, sleep disorders, or preoperative delirium. These conditions are prevalent in elderly hip surgery patients and are well-established predisposing factors for PND and POD. For instance, preoperative depression has been linked to a 2.5-fold increased risk of POD, while sleep disturbances correlate with prolonged cognitive dysfunction post-surgery.
Furthermore, the study omitted critical baseline data, including preoperative hemoglobin and albumin levels. Anemia (hemoglobin <10 g/dL) and hypoalbuminemia (albumin <3.5 g/dL) are independent risk factors for POD, contributing to tissue hypoxia and impaired drug metabolism. Similarly, the authors did not report preoperative medication use, particularly anticholinergic drugs and benzodiazepines, which are associated with a 30–40% higher risk of delirium in elderly patients. Without controlling for these variables, the observed differences between groups may reflect imbalances in baseline characteristics rather than the true effect of edaravone.
2. Diagnostic Criteria for PND
The study’s definition of PND relied solely on declines in TICS-m scores, which raises concerns about diagnostic validity. In 2018, the International Nomenclature Consensus Working Group emphasized that PND diagnoses must align with the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for neurocognitive disorders. The DSM-5 requires evidence of cognitive decline in one or more domains (e.g., memory, attention, executive function) that interferes with independence, alongside exclusion of other medical or psychiatric causes.
By depending exclusively on TICS-m scores—a screening tool designed for telephonic assessments—the study may have overestimated PND incidence. The TICS-m lacks sensitivity to domain-specific cognitive impairments and does not evaluate functional decline, a core component of DSM-5 criteria. Consequently, the reported PND rates may not accurately reflect clinically significant neurocognitive disorders, undermining the validity of the conclusions.
3. Postoperative Complications and Hospital Stay
Although the edaravone group experienced shorter hospital stays, the study did not elucidate the reasons for prolonged hospitalization in the control group. Early postoperative complications, such as infections (e.g., surgical site infections, pneumonia), hemodynamic instability, arrhythmias, and anemia, are common in elderly patients and directly influence recovery trajectories. For example, postoperative anemia (hematocrit <30%) is associated with a 20–30% longer hospital stay due to delayed mobility and rehabilitation.
The absence of data on postoperative complications prevents a comprehensive understanding of edaravone’s benefits. Standardizing perioperative care protocols—including pain management, infection prophylaxis, and early mobilization—is essential to isolate the effect of edaravone on PND and POD. Without such standardization, confounding factors may have skewed the observed reduction in hospital stay.
4. Statistical and Study Design Considerations
The trial’s statistical methodology raised concerns about endpoint prioritization and multiple testing. The authors designated three primary endpoints—POD incidence, TICS-m scores, and ADL scores—but calculated the sample size based on the incidence of cognitive decline. This approach violates the principle of designing sample size calculations around a single primary endpoint. Moreover, analyzing multiple endpoints without adjusting significance thresholds (e.g., Bonferroni correction) increases the risk of Type I errors (false positives).
For instance, if a p-value threshold of 0.05 is applied to three endpoints, the probability of at least one false-positive finding rises to 14.3%. Transparent reporting of statistical adjustments is critical to ensuring the reliability of the results, particularly in studies with multiple interrelated outcomes.
Mechanistic Insights and Edaravone’s Role
Edaravone’s potential efficacy in reducing PND and POD may stem from its antioxidative and anti-inflammatory properties. The study reported a significant decrease in serum CXCL13 levels in the edaravone group postoperatively. CXCL13, a chemokine involved in neuroinflammation and blood-brain barrier disruption, is elevated in neurodegenerative conditions such as Alzheimer’s disease. By scavenging free radicals and suppressing pro-inflammatory cytokines, edaravone may mitigate neuronal damage and synaptic dysfunction induced by surgical stress.
However, the study did not measure other biomarkers of oxidative stress (e.g., malondialdehyde, superoxide dismutase) or neuroinflammation (e.g., interleukin-6, tumor necrosis factor-alpha), limiting the mechanistic interpretation. Future research should integrate multimodal biomarker assessments to elucidate edaravone’s neuroprotective pathways.
Clinical Implications and Future Directions
Despite its limitations, the study highlights edaravone as a promising adjuvant therapy for reducing PND and POD in high-risk elderly patients. However, translating these findings into clinical practice requires addressing the methodological gaps identified. Key recommendations include:
- Comprehensive Preoperative Assessments: Routine screening for neuropsychiatric comorbidities, medication histories, and nutritional status (hemoglobin, albumin) to identify high-risk patients.
- Standardized Diagnostic Criteria: Adherence to DSM-5 guidelines for PND diagnosis, incorporating domain-specific cognitive testing and functional assessments.
- Standardization of Perioperative Care: Protocolized management of pain, infections, and hemodynamic stability to minimize confounding factors.
- Robust Statistical Frameworks: Clear designation of a single primary endpoint with appropriate sample size calculations and adjustments for multiple comparisons.
Conclusion
The trial by Xi et al. provides preliminary evidence supporting edaravone’s role in reducing neurocognitive complications after hip replacement surgery. However, the study’s limitations underscore the need for rigorous methodological frameworks in perioperative research. By addressing these gaps, future trials can establish edaravone’s efficacy and optimize perioperative care for elderly surgical patients.
doi.org/10.1097/CM9.0000000000001973
Was this helpful?
0 / 0